C4 Therapeutics, Inc. Stock price

Equities

CCCC

US12529R1077

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 11:54:01 2024-03-28 am EDT 5-day change 1st Jan Change
8.155 USD +1.30% Intraday chart for C4 Therapeutics, Inc. -6.43% +44.25%
Sales 2024 * 26.34M Sales 2025 * 21.24M Capitalization 552M
Net income 2024 * -139M Net income 2025 * -154M EV / Sales 2024 * 11.3 x
Net cash position 2024 * 254M Net cash position 2025 * 244M EV / Sales 2025 * 14.5 x
P/E ratio 2024 *
-4.17 x
P/E ratio 2025 *
-4.04 x
Employees 145
Yield 2024 *
-
Yield 2025 *
-
Free-Float 66.14%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.39%
1 week-9.14%
Current month-26.68%
1 month-17.44%
3 months+56.92%
6 months+344.75%
Current year+42.48%
More quotes
1 week
7.76
Extreme 7.76
8.69
1 month
7.76
Extreme 7.76
11.88
Current year
5.00
Extreme 5
11.88
1 year
1.06
Extreme 1.06
11.88
3 years
1.06
Extreme 1.06
51.21
5 years
1.06
Extreme 1.06
51.21
10 years
1.06
Extreme 1.06
51.21
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 20-09-13
Director of Finance/CFO 48 20-11-19
Chief Tech/Sci/R&D Officer - 20-12-31
Members of the board TitleAgeSince
Chairman 76 15-11-30
Director/Board Member 67 21-03-11
Corporate Officer/Principal 55 15-11-30
More insiders
Date Price Change Volume
24-03-28 8.143 +1.16% 392 629
24-03-27 8.05 +1.39% 1,742,395
24-03-26 7.94 -3.29% 1,814,659
24-03-25 8.21 -0.12% 1,284,465
24-03-22 8.22 -5.63% 1,192,855

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing targeted protein degradation science to develop a new generation of small-molecule medicines to transform how disease is treated. It leverages its technology platform, Target ORiented ProtEin Degrader Optimizer (TORPEDO), to design and optimize small-molecule medicines that harness the body's natural protein recycling system to rapidly degrade disease-causing proteins. Its TORPEDO platform enables the discovery of targeted investigational small molecule medicines called protein degraders. Its advanced product candidate, CFT7455, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3, which are in clinical development for multiple myeloma (MM), and non-Hodgkin lymphomas (NHLs). Its other product candidate, CFT8634, is an orally bioavailable BiDAC degrader of a protein target called BRD9 for the treatment of synovial sarcoma and SMARCB1-null solid tumors.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
8.05 USD
Average target price
17.22 USD
Spread / Average Target
+113.94%
Consensus
  1. Stock
  2. Equities
  3. Stock C4 Therapeutics, Inc. - Nasdaq